{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:36:10Z","timestamp":1793147770325,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jgo.2025.102219","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T16:44:43Z","timestamp":1741452283000},"page":"102219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study"],"prefix":"10.1016","volume":"16","author":[{"given":"Enrica Antonia","family":"Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fragliasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corsonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl l","key":"10.1016\/j.jgo.2025.102219_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/107327481502204s04","article-title":"Management of chronic lymphocytic leukemia in the elderly","volume":"22","author":"Barrientos","year":"2015","journal-title":"Cancer Control"},{"key":"10.1016\/j.jgo.2025.102219_bb0010","doi-asserted-by":"crossref","unstructured":"Eichhorst, B. et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia Ann Oncol, Volume 35, Issue 9, 762\u2013768.","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"10.1016\/j.jgo.2025.102219_bb0020","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s11912-022-01322-z","article-title":"How have targeted agents changed the treatment landscape for elderly patients with CLL?","volume":"24","author":"Rhodes","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jgo.2025.102219_bb0025","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jgo.2025.102219_bb0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2025.102219_bb0035","first-page":"1645","article-title":"Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment","author":"Caillet","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"26","key":"10.1016\/j.jgo.2025.102219_bb0040","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102219_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/annonc\/mdt386","article-title":"An update on a systematic review of the use of geriatric assessment for older adults in oncology","volume":"2","author":"Puts","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2025.102219_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgo.2013.04.002","article-title":"Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment","volume":"3","author":"Ramjaun","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2025.102219_bb0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) task force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2025.102219_bb0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2025.102219_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jgo.2025.102219_bb0070","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.jgo.2025.102219_bb0075","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2025.102219_bb0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5770\/cgj.23.463","article-title":"Using the clinical frailty scale in allocating scarce health care resources","volume":"23","author":"Rockwood","year":"2020","journal-title":"Can Geriat J"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2025.102219_bb0085","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2023-187262","article-title":"Polypharmacy independently predicts overall survival in patients with lymphoid cancer","volume":"142","author":"Brieghel","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2025.102219_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bjh.14033","article-title":"Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study","volume":"174","author":"Buckstein","year":"2016","journal-title":"Br J Haematol"},{"issue":"s1","key":"10.1016\/j.jgo.2025.102219_bb0095","first-page":"0154","article-title":"Cumulative illness rating scale (CIRS) is a valuable tool to assess and weigh comorbidity in patients with chronic lymphocytic leukemia: results for the CLL8 trial of the German CLL study group","volume":"97","author":"Goede","year":"2012","journal-title":"EHA Haematol"},{"issue":"11","key":"10.1016\/j.jgo.2025.102219_bb0100","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jgo.2025.102219_bb0105","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jgo.2025.102219_bb0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of Venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jgo.2025.102219_bb0115","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2025.102219_bb0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00432-010-0933-5","article-title":"Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma","volume":"137","author":"Winkelmann","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102219_bb0125","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-013-2001-0","article-title":"The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with haematological malignancy","volume":"93","author":"Hamaker","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jgo.2025.102219_bb0130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","article-title":"A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients","volume":"60","author":"Molica","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.jgo.2025.102219_bb0135","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.2023020195","article-title":"Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL","volume":"142","author":"van der Straten","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2025.102219_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101538","article-title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","volume":"14","author":"Johnson","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"17","key":"10.1016\/j.jgo.2025.102219_bb0145","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jgo.2025.102219_bb0150","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","article-title":"A scoping review of the clinical frailty scale","volume":"20","author":"Church","year":"2020","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgo.2025.102219_bb0155","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2016.129","article-title":"Decrease in total protein level of bruton\u2019s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes","volume":"30","author":"Cervantes-Gomez","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jgo.2025.102219_bb0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T18:02:21Z","timestamp":1744480941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1879406825000359"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102219","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102219"}}